Post-essential Thrombocythemia Myelofibrosis
📧 Sign up to get email alerts when something new happens for Post-essential Thrombocythemia Myelofibrosis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2024-07-30FDA Approved: INREBIC — Supplemental Application (Celgene Corporation)
FDA approved a supplemental application for INREBIC (fedratinib hydrochloride) from Celgene Corporation (NDA 212327).